- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04266015
Anabolic Effects of Intraoperative Feeding in Reconstruction Surgery
A Randomized Trial of Intraoperative Feeding to Ameliorate Catabolic Response in Free Flap Reconstruction Surgery for Head-and-neck Cancer Defect
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Perioperative fasting remains a common clinical practice in surgical patients, aiming to prevent pulmonary aspiration during anesthesia induction, improve bowel preparation, and ameliorate the development of postoperative nausea/vomiting or other surgical-related complications. Major head-and-neck tumor excision and reconstruction surgery is one of the most time-consuming surgeries that usually takes more than 12 h to complete. In addition to the preoperative fasting and postoperative recovery time periods, most of these patients will be fasted for more than 24-36 h before they are fed via nasogastric tubes in the postoperative care units. The combination catabolic effects resulted from prolonged perioperative fasting and profound surgical stress are likely to induce extensive protein catabolism, muscle breakdown and impaired glycemic control during postoperative phase. These catabolic responses may lead to the development of post-operative surgical site infection, delayed wound healing, re-intervention, cardiac arrest, and death in diabetic and non-diabetic patients. Furthermore, prolonged gastrointestinal fasting is associated with dehydration, perturbed gut integrity/permeability (leaky gut) and microbial (bacterial) translocation that deteriorates the early recovery after reconstruction surgery. The aim of this clinical trial is to test the effect of intraoperative feeding in patients receiving head-and-neck tumor excision and reconstruction surgery, and anticipate that reduction of perioperative fasting time may improve intraoperative hemodynamics and enhance postoperative recovery due to attenuation of systemic catabolism and improvement of insulin sensitivity to glycemic control.
This single-center clinical trial will be undertaken in a randomized, double-blind, placebo-controlled fashion, in which patients with advanced head-and-neck tumor who are scheduled for extended tumor resection and free-flap reconstruction will be randomly assigned to receive control (no intraoperative feeding) or intraoperative feeding group. Feeding via the nasogastric (NG) tube will start after the establishment of tracheostomy and completion of tumor resection at fusion rate of 10-30 ml/h (feeding diet 1 Kcal/ml and 0.04 g protein/ml). This trial anticipates in detecting differences in intraoperative hemodynamic stability and development of major postoperative complications, including delayed wound healing, surgical site infections and insulin-resistant hyperglycemia between controls and intraoperative feeding group. The outcomes of this clinical trial may provide fundamental evidence for vigorous enteric nutrition and energy support during prolonged high surgical stress operation.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Kaohsiung
-
Yanchao, Kaohsiung, Taiwan, 824
- E-Da Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Advanced head-and-neck cancer
- Requires radical resection, tracheostomy and free flap reconstruction surgery
Exclusion Criteria:
- Anticipated total operation time < 6h
- Emergency operation
- Bowel obstruction
- Starts nasogastric feeding before operation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control group
Patients assigned to control group will not receive feeding via the nasogastric tube during operation
|
|
Experimental: Intraoperative feeding group
Patients assigned to intraoperative feeding group will receive enteral nutrition formula via the nasogastric tube during operation
|
Intervention group will receive nasogastric feeding with commercially available liquid enteral diet (250 ml/can, Kcal/ml, 10.4 g protein/can) during free flap reconstruction at feeding rates 10-30 ml/h.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants that have reconstruction flap failure after operation
Time Frame: 7 days after free flap reconstruction
|
The definition of flap failure includes vascular occlusion of flap, surgical wound infection or poor healing that requires surgical reintervention
|
7 days after free flap reconstruction
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants that have perioperative complications
Time Frame: Start of free flap reconstruction surgery to 28 days after operation
|
The definition of composite perioperative complications during and after operation, include intraoperative hemodynamic stability (hypotension and requirement of inotropes), postoperative insulin sensitivity, glycemic control, skeletal muscle wasting, inflammatory cytokine profiles, length of hospital stay, re-intervention, other postoperative complications, mortality during hospital stay
|
Start of free flap reconstruction surgery to 28 days after operation
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Chen-Fuh Lam, MD, PhD, E-Da Hospital, Taiwan
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Glucose Metabolism Disorders
- Metabolic Diseases
- Nervous System Diseases
- Neoplasms
- Neoplasms by Site
- Neurologic Manifestations
- Neuromuscular Manifestations
- Pathological Conditions, Anatomical
- Atrophy
- Hyperglycemia
- Head and Neck Neoplasms
- Muscular Atrophy
- Postoperative Complications
Other Study ID Numbers
- EMRP71108N
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Neoplasms
-
Robert FerrisAmgenCompletedHead and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neoplasms, Head and Neck | Cancer of the Head and Neck | Cancer of Neck | Upper Aerodigestive Tract Neoplasms | Neck Neoplasms | Cancer of the Head | Cancer of the Neck | UADT Neoplasms | Cancer of Head | Head Neoplasms | Head, Neck Neoplasms | Neoplasms, Head and other conditionsUnited States
-
Assiut UniversityRecruitingHead and Neck Cancer | Head and Neck Neoplasms | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and NeckEgypt
-
IRCCS Policlinico S. MatteoNestlé Health Science Spain; Akern SrlCompletedHead-neck CancerItaly
-
University of California, San FranciscoCompleted
-
AZ Sint-Jan AVRecruiting
-
IntraGel TherapeuticsNot yet recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHead and Neck CarcinomaUnited States
-
Gustave Roussy, Cancer Campus, Grand ParisActive, not recruiting
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Completed
-
Jonsson Comprehensive Cancer CenterWithdrawnHead and Neck CarcinomaUnited States
Clinical Trials on Enteral nutrition formula
-
Medical University of WarsawUnknownPancreatic Cancer | Cholangiocarcinoma | Chronic Pancreatitis | Cancer of the DuodenumPoland
-
Société des Produits Nestlé (SPN)CompletedDiabetesUnited States
-
Brno University HospitalRecruitingEnteral Feeding IntoleranceCzechia
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WithdrawnClinical Stage III Esophageal Adenocarcinoma AJCC v8 | Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8 | Pathologic Stage III Esophageal Adenocarcinoma AJCC v8 | Pathologic Stage III Esophageal Squamous Cell Carcinoma AJCC v8 | Pathologic Stage IIIA Esophageal Adenocarcinoma... and other conditionsUnited States
-
Hospital Moinhos de VentoCompleted
-
University of Alabama at BirminghamActive, not recruitingEnteral Feeding Intolerance | Premature; Infant, Light-for-datesUnited States
-
Second Affiliated Hospital, School of Medicine,...Unknown
-
Nanjing University School of MedicineJinling Hospital, ChinaCompletedAcute Pancreatitis | Intra-abdominal HypertensionChina
-
Shanghai Zhongshan HospitalRenJi Hospital; Shanghai 10th People's Hospital; Shanghai Tong Ren Hospital; Xinhua... and other collaboratorsSuspended
-
Société des Produits Nestlé (SPN)Completed